Inflammation & Immunology

Parexel’s experience in rheumatology includes key studies in multiple indications such as rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriatic arthritis, ankylosing spondylitis, and gout. Led by a board-certified rheumatologist, our team has expertise including adjudication in complex diseases such as SLE. We are a full-service provider that can partner with you from Early Phase trials conducted in our own Early Phase Clinical Units to global Phase II-VI trials. Our site network and global footprint allow us to access key patient populations necessary in ensuring representative clinical trials.

Parexel’s work in dermatology studies ranges from Early Phase trials conducted both in our own Early Phase Clinical Units (EPCUs) to complex global trials in Phase II-IV, together with substantial regulatory drug development. Our extensive late-phase experience includes the largest Phase III moderate-to-severe plaque psoriasis program to date. We are also experienced in conducting trials in niche areas such vitiligo, hidradenitis suppurativa and prurigo nodularis. Our network of EPCUs offers access to multiple patient populations and healthy volunteers, and can provide true study feasibility assessments based on actual experience.

An overarching strength at Parexel is our extensive therapeutic area expertise example, in relation to inflammatory bowel diseases, which often overlap with other diseases that can cause inflammation of the large intestine. Led by a board-certified gastroenterologist, our experienced team plays a critical role on the path to approval. Through collaboration with experts in other therapeutic areas, such as in immunology, we provide a comprehensive solution for challenges with study design, operational considerations, and endpoint evaluation.